Primary Ewing’s sarcoma of the kidney: description of two rare clinical cases and review of world literature

Ewing’s sarcoma (ES) of the kidney is an extremely rare malignant tumor characterized by an aggressive course, and therefore the disease has an unfavorable prognosis. Due to the rare occurrence, standards for the treatment of ES of the kidney have not been developed; an integrated approach is often used in therapy. In this article, we present a description of two clinical cases of kidney damage with ES in patients aged 10 and 16 who were treated at the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia. In the first case, there was a metastatic lesion of the kidney with the localization of the primary focus in the pelvic bones, in the second, primary ES of the kidney was diagnosed. Both patients had stage IVb at the time of diagnosis (TNM classification American Joint Commission on Cancer). In both patients, after induction chemotherapy, a complete therapeutic response (complete therapeutic pathomorphosis) was obtained. In an integrated approach, in addition to standard chemotherapy, surgery and radiation therapy, in both cases, high-dose chemotherapy with autologous peripheral stem cell transplantation was used, which made it possible to create favorable conditions for long-term remission in one of the patients, even despite the initial prevalence of the process.

1. Zhang S., Li Y., Wang R., Song B. Ewing’s sarcoma/primitive neuroectodermal tumor of the kidney: a case report and literature review. Transl Androl Urol. 2019;8(5):562–6. doi: 10.21037/tau.2019.09.46.

2. Ellinger J., Bastian P.J., Hauser S., Biermann K., Müller S.C. Primitive neuroectodermal tumor: Rare, highly aggressive diff erential diagnosis in urologic malignancies. Urology. 2006;68:257–62. doi: 10.1016/j.urology.2006.02.037.

3. Seemayer T., Thelmo W., Bolande R. Peripheral neuroectodermal tumors. Perspect Pediatr Pathol. 1975;2:151–72. PMID: 1129029.

4. Romantsova O.M., Khestanov D.B., Dzampaev A.Z., Khairullova V.V., Efi mova M.M., Gorbunova T.V., Kirgizov K.I., Varfolomeeva S.R. Bone and extraskeletal Ewing’s sarcoma: comparative characteristics of the course and outcomes of the disease. Experience of the Research Institute of Pediatric Oncology and Hematology named after L.A. Durnov with the N.N. Blokhin Russian Cancer Research Center. Pediatriya. Zhurnal im. G.N. Speranskogo = Pediatrics. Journal n.a. G.N. Speransky. 2023;102(3):41–50. (In Russ.).

5. Choi J.H., Ro J.Y. The 2020 WHO Classifi cation of Tumors of Soft Tissue: Selected Changes and New Entities Adv Anathomy Pathor. 2021;28(1):44–58. doi: 10.1097/PAP.0000000000000284.

6. Welsch T., Mechtersheimer G., Aulmann S., Mueller S.A., Buechler M.W., Schmidt J., Kienle P. Huge primitive neuroectodermal tumor of the pancreas: Report of a case and review of the literature. World J Hastroenterol. 2006;12(37):6070–3. doi: 10.3748/wjg.v12.i37.6070.

7. Nisichenko O.A., Dolgopolov I.S., Nisichenko D.V., Malakhova A.A., Romantsova O.M., Hestanov D.B., Dzampaev A.Z. Defi nition of treatment strategy for children and adolescents with ewing sarcoma in primary pelvic bone injury. Sarkomy Kostei Miagkikh Tkanei I Opukholi Kozhi = Bone and Soft Tissue Sarcomas, Tumors of the Skin. 2020;12(2–3):45–53. (In Russ.).

8. Tarek N., Said R., Andersen C.R., Suki T.S., Foglesong J., Herzog C.E., Tannir N.M., Patel S., Ratan R., Ludwig J.A., Daw N.C. Primary Ewing Sarcoma Primitive Neoriectodermal Tumor of the Kidney: The MD Anderson Cancer Center Expirience Cancers (Basel), 2020. doi: 10.3390/cancers12102927.

9. Cheng L., Xu Y., Song H., Huang H., Zhuo D. A rare entity of Primary Ewing sarcoma in kidney. BMC Surg. 2020;20(1):280. doi: 10.1186/s12893-020-00948-9.

10. Alghamdi M.H.A., Alawad S.A., Alharbi M.G., Alabdulsalam A.K., Almodhen F., Alasker A. A rare case of Ewing’s sarcoma of the kidney. Urol Case Rep. 2019:29:101094. doi: 10.1016/j.eucr.2019.101094.

11. Brown H.K., Schiavone K., Gouin F., Heymann M.F., Heymann D. Biology of Bone Sarcomas and New Therapeutic Developments. Calcif Tissue Int. 2018;102(2):174–95. doi: 10.1007/s00223-017-0372-2.

12. Thyavihally Y.B., Tongaonkar H.B., Gupta S., Kurkure P.A., Amare P., Muckaden M.A., Desai S.B. Primitive Neuroectodermal Tumor of the Kidney: A Single Institute Series of 16 Patients. Urology. 2008;71:292–6. doi: 10.1016/j.urology.2007.09.051.

13. Karpate A., Menon S., Basak R., Yuvaraja T.B., Tongaonkar H.B., Desai S.B. Ewing sarcoma/primitive neuroectodermal tumor of the kidney: Clinicopathologic analysis of 34 cases. Ann Diagn Pathol 2012;16:267–74. doi: 10.1016/j.anndiagpath.2011.07.011.

14. Hakky T.S., Gonzalvo A.A., Lockhart J.L., Rodriguez A.R. Primary Ewing sarcoma of the kidney: A symptomatic presentation and review of the literature. Ther Adv Urol. 2012;5:153–9. doi: 10.1177/1756287212471095.

15. Applebaum M.A., Worch J., Matthay K.K., Goldsby R., Neuhaus J., West D.C., Dubois S.G. Clinical features and outcomes in patients with extraskeletal ewing sarcoma. Cancer. 2011;117:3027–32. doi: 10.1002/cncr.25840.

16. Miller R.W. Contrasting epidemiology of childhood osteosarcoma, Ewing’s tumor, and rhabdomyosarcoma. Natl Cancer Inst Monogr. 1981;56:9–15. PMID: 7029300.

17. Cotterill S., Ahrens S., Paulussen M., Jürgens H., Voûte P., Gadner H., Craft A. Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18:3108–14. doi: 10.1200/JCO.2000.18.17.3108.

18. Rodriguez-Galindo C., Liu T., Krasin M.J., Wu J., Billups C.A., Daw N.C., Spunt S.L., Rao B.N., Santana V.M., Navid F. Analysis of prognostic factors in ewing sarcoma family of tumors. Cancer. 2007;110:375–84. doi: 10.1002/cncr.22821.

19. Risi E., Iacovelli R., Altavilla A., Alesini D., Palazzo A., Mosillo C., Trenta P., Cortesi E. Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the Kidney. Urology. 2013;82:382–6. doi: 10.1016/j.urology.2013.04.015.

20. Rowe R.G., Thomas D., Schuetze S.M., Hafez K.S., Lawlor E.R., Chugh R. Ewing Sarcoma of the Kidney: Case Series and Literature Review of an Often Overlooked Entity in the Diagnosis of Primary Renal Tumors. Urololgy. 2013;81:347–53. doi: 10.1016/j.urology.2012.10.016.

21. Zöllner S., Dirksen U., Jürgens H., Ranft A. Renal Ewing tumors. Ann Oncol. 2013;24:2455–61. doi: 10.1093/annonc/mdt215.

22. Valiev T.T., Panferova T.R., Koshechkina N.A., Zakharova E.V., Mikhailova E.V., Kaminskaya I.V. Kidney damage in non-Hodgkin’s lymphomas in children. Sovremennaya onkologiya = Modern Oncology. 2014;16(1):53–9. (In Russ.).

23. Huang J., Zhang J., Dong B., Clien Y., Kong W., Liu Q. Primitive neuroectodermal tumor of the kidney: a single-institute series of six patients from China. Urol Int. 2013;90:174–8. doi: 10.1159/000342647.

24. Rodriguez-Galindo C., Marina N.M., Fletcher B.D., Parham D.M., Bodner S.M., Meyer W.H. Is primitive neuroectodermal tumor of the kidney a distinct entity? Cancer. 1997;79:2243–50. doi: 10.1002/ (SICI)1097-0142(19970601)79:11<2243::AID-CNCR24>3.0.CO;2-V.

25. Grier H.E., Krailo M.D., Tarbell N.J., Link M.P., Fryer C.J.H., Pritchard D.J., Gebhardt M.C., Dickman P.S., Perlman E.J., Meyers P.A., Donaldson S.S., Moore S., Rausen A.R., Vietti T.J., Miser J.S. Addition of Ifosfamide and Etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701. doi: 10.1056/NEJMoa020890.

26. Womer R.B., West D.C., Krailo M.D., Dickman P.S., Pawel B.R., Grier H.E., Marcus K., Sailer S., Healey J.H., Dormans J.P., Weiss A.R. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Childrenʼs Oncology Group. J Clin Oncol. 2012;30(33):4148–54. doi: 10.1200/JCO.2011.41.5703.

27. Juergens C., Weston C., Lewis I., Whelan J., Paulussen M., Oberlin O., Michon J., Zoubek A., Juergens H., Craft A. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EUROE.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006;47(1):22–9. doi: 10.1002/pbc.20820.

28. Wagner M.J., Ravi V., Livingston J.A., Conley A.P., Araujo D., Somaiah N., Zarzour M.A., Ratan R., Wang W.-L., Patel S.R., Lazar A., Ludwig J.A., Benjamin R.S. Vincristine, ifosfamide, and doxorubicin for initial treatment of Ewing sarcoma in adults. Oncologist. 2017;22(10):1271–7. doi: 10.1634/theoncologist.2016-0464.

29. Chakrabarti N., Dewasi N., Das S., Bandyopadhyay A., Bhadure N. Primary Ewing’ s sarcoma/primitive neuroectodermal tumor of kidney – a diagnostic dilemma. Iran J Cancer Prev. 2015;8(2):129–33. PMID: 25960853.

30. Kuczynski A.P., Gugelmin E.S., Netto R.A.S. Primitive neuroectodermal tumor of the kidney in children. J Pediatia. 2001;77(1):49–51. doi: 10.2223/JPED.111.